Tumor necrosis factor inhibitors are an effective treatment for psoriatic arthritis, but no single agent is effective in all patients. Novel therapies that target other cytokines have now been tested, with encouraging results.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gladman, D. D. Psoriatic arthritis. Dermatol. Ther. 22, 40–55 (2009).
Gottlieb, A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373, 633–640 (2009).
Soriano, E. R. & McHugh, N. J. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J. Rheumatol. 33, 1422–1430 (2006).
Ribbens, C. et al. Increased synovial fluid levels of interleukin-12, sCD25 and sTNF-RII/sTNF-RI ratio delineate a cytokine pattern characteristic of immune arthropathies. Eur. Cytokine Netw. 11, 669–676 (2000).
Hueber, A. J. & McInnes, I. B. Immune regulation in psoriasis and psoriatic arthritis—recent developments. Immunol. Lett. 114, 59–65 (2007).
Ravindran, V., Scott, D. L. & Choy, E. H. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann. Rheum. Dis. 67, 855–859 (2008).
Nair, R. P. et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat. Genet. 41, 199–204 (2009).
Hüffmeier, U. et al. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J. Invest. Dermatol. 129, 355–358 (2009).
Rahman, P. et al. Association of interleukin-23R variants with psoriatic arthritis. J. Rheumatol. 36, 137–140 (2009).
Krueger, G. G. et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356, 580–592 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Gladman, D. Targeted therapy for psoriatic arthritis. Nat Rev Rheumatol 5, 241–242 (2009). https://doi.org/10.1038/nrrheum.2009.76
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2009.76
This article is cited by
-
Psoriatic Arthritis in South and Central America
Current Rheumatology Reports (2011)